Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer

Hanbyoul Cho, Jane Seon Young Kim, Hyunsoo Chung, Candice Perry, Heejeong Lee, Jae-Hoon Kim

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The tumor suppressor gene ARID1A encodes BAF250a, a component of human SWI/SNF chromatin-remodeling complexes. Loss of BAF250a expression has recently been reported in several tumor types. To investigate the potential correlation between BAF250a and various clinicopathologic parameters, we assessed the expression of BAF250a in archival tumor tissue specimens from 147 patients with cervical cancer and 191 with cervical intraepithelial neoplasia as well as 376 matched nonadjacent normal tissues by immunohistochemical staining. Messenger RNA expression level for BAF250a was decreased in cervical cancer cell lines (P =.013) and tissues (P =.010), when compared with normal cervical epithelial tissue using SYBR Green real-time polymerase chain reaction. BAF250a was also detected in nuclear fractions of HeLa cells and in nuclei of cervical cancer tissue samples by Western blotting and immunohistochemistry, respectively. BAF250a expression gradually decreased in transitioning from normal to cervical carcinoma (P <.001), and this loss of expression was significantly associated with tumor stage (P =.005), tumor grade (P =.029), tumor size (P =.003), and lymph node metastasis (P =.020). In multivariate analysis, overall survival in cervical cancer was significantly reduced in cases with BAF250a loss (hazard ratio, 2.78 [1.01-7.63]; P =.047). Our findings suggest a potential role for BAF250a in providing valuable prognostic information to clinicians for risk assessment in cervical cancer.

Original languageEnglish
Pages (from-to)1365-1374
Number of pages10
JournalHuman Pathology
Volume44
Issue number7
DOIs
Publication statusPublished - 2013 Jul 1

Fingerprint

Uterine Cervical Neoplasms
Neoplasms
Cervical Intraepithelial Neoplasia
Chromatin Assembly and Disassembly
Tumor Suppressor Genes
Cell Nucleus
HeLa Cells
Real-Time Polymerase Chain Reaction
Multivariate Analysis
Epithelium
Lymph Nodes
Western Blotting
Immunohistochemistry
Staining and Labeling
Neoplasm Metastasis
Carcinoma
Cell Line
Messenger RNA
Survival

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Cho, Hanbyoul ; Kim, Jane Seon Young ; Chung, Hyunsoo ; Perry, Candice ; Lee, Heejeong ; Kim, Jae-Hoon. / Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. In: Human Pathology. 2013 ; Vol. 44, No. 7. pp. 1365-1374.
@article{76d6e5b0a5a8415c886dbf7ea554cbfe,
title = "Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer",
abstract = "The tumor suppressor gene ARID1A encodes BAF250a, a component of human SWI/SNF chromatin-remodeling complexes. Loss of BAF250a expression has recently been reported in several tumor types. To investigate the potential correlation between BAF250a and various clinicopathologic parameters, we assessed the expression of BAF250a in archival tumor tissue specimens from 147 patients with cervical cancer and 191 with cervical intraepithelial neoplasia as well as 376 matched nonadjacent normal tissues by immunohistochemical staining. Messenger RNA expression level for BAF250a was decreased in cervical cancer cell lines (P =.013) and tissues (P =.010), when compared with normal cervical epithelial tissue using SYBR Green real-time polymerase chain reaction. BAF250a was also detected in nuclear fractions of HeLa cells and in nuclei of cervical cancer tissue samples by Western blotting and immunohistochemistry, respectively. BAF250a expression gradually decreased in transitioning from normal to cervical carcinoma (P <.001), and this loss of expression was significantly associated with tumor stage (P =.005), tumor grade (P =.029), tumor size (P =.003), and lymph node metastasis (P =.020). In multivariate analysis, overall survival in cervical cancer was significantly reduced in cases with BAF250a loss (hazard ratio, 2.78 [1.01-7.63]; P =.047). Our findings suggest a potential role for BAF250a in providing valuable prognostic information to clinicians for risk assessment in cervical cancer.",
author = "Hanbyoul Cho and Kim, {Jane Seon Young} and Hyunsoo Chung and Candice Perry and Heejeong Lee and Jae-Hoon Kim",
year = "2013",
month = "7",
day = "1",
doi = "10.1016/j.humpath.2012.11.007",
language = "English",
volume = "44",
pages = "1365--1374",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "7",

}

Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. / Cho, Hanbyoul; Kim, Jane Seon Young; Chung, Hyunsoo; Perry, Candice; Lee, Heejeong; Kim, Jae-Hoon.

In: Human Pathology, Vol. 44, No. 7, 01.07.2013, p. 1365-1374.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer

AU - Cho, Hanbyoul

AU - Kim, Jane Seon Young

AU - Chung, Hyunsoo

AU - Perry, Candice

AU - Lee, Heejeong

AU - Kim, Jae-Hoon

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The tumor suppressor gene ARID1A encodes BAF250a, a component of human SWI/SNF chromatin-remodeling complexes. Loss of BAF250a expression has recently been reported in several tumor types. To investigate the potential correlation between BAF250a and various clinicopathologic parameters, we assessed the expression of BAF250a in archival tumor tissue specimens from 147 patients with cervical cancer and 191 with cervical intraepithelial neoplasia as well as 376 matched nonadjacent normal tissues by immunohistochemical staining. Messenger RNA expression level for BAF250a was decreased in cervical cancer cell lines (P =.013) and tissues (P =.010), when compared with normal cervical epithelial tissue using SYBR Green real-time polymerase chain reaction. BAF250a was also detected in nuclear fractions of HeLa cells and in nuclei of cervical cancer tissue samples by Western blotting and immunohistochemistry, respectively. BAF250a expression gradually decreased in transitioning from normal to cervical carcinoma (P <.001), and this loss of expression was significantly associated with tumor stage (P =.005), tumor grade (P =.029), tumor size (P =.003), and lymph node metastasis (P =.020). In multivariate analysis, overall survival in cervical cancer was significantly reduced in cases with BAF250a loss (hazard ratio, 2.78 [1.01-7.63]; P =.047). Our findings suggest a potential role for BAF250a in providing valuable prognostic information to clinicians for risk assessment in cervical cancer.

AB - The tumor suppressor gene ARID1A encodes BAF250a, a component of human SWI/SNF chromatin-remodeling complexes. Loss of BAF250a expression has recently been reported in several tumor types. To investigate the potential correlation between BAF250a and various clinicopathologic parameters, we assessed the expression of BAF250a in archival tumor tissue specimens from 147 patients with cervical cancer and 191 with cervical intraepithelial neoplasia as well as 376 matched nonadjacent normal tissues by immunohistochemical staining. Messenger RNA expression level for BAF250a was decreased in cervical cancer cell lines (P =.013) and tissues (P =.010), when compared with normal cervical epithelial tissue using SYBR Green real-time polymerase chain reaction. BAF250a was also detected in nuclear fractions of HeLa cells and in nuclei of cervical cancer tissue samples by Western blotting and immunohistochemistry, respectively. BAF250a expression gradually decreased in transitioning from normal to cervical carcinoma (P <.001), and this loss of expression was significantly associated with tumor stage (P =.005), tumor grade (P =.029), tumor size (P =.003), and lymph node metastasis (P =.020). In multivariate analysis, overall survival in cervical cancer was significantly reduced in cases with BAF250a loss (hazard ratio, 2.78 [1.01-7.63]; P =.047). Our findings suggest a potential role for BAF250a in providing valuable prognostic information to clinicians for risk assessment in cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=84879222020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879222020&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2012.11.007

DO - 10.1016/j.humpath.2012.11.007

M3 - Article

C2 - 23427874

AN - SCOPUS:84879222020

VL - 44

SP - 1365

EP - 1374

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 7

ER -